



Office of the Secretary

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

January 18, 2007

David A. Clanton, Esq.
Baker & McKenzie, LLP
815 Connecticut Avenue, NW
Washington, DC 20006-4078
(202) 452-7074

Re: *In the Matter of Hospira, Inc., and Mayne Pharma Limited*
FTC File No. 071 0002, Docket No. C-4182

Dear Mr. Clanton:

This letter notifies Hospira, Inc. (“Hospira”) that the Federal Trade Commission has approved the appointment of Owen Richards, President of Quantic Regulatory Services, LLC as the Interim Monitor, and has approved the Interim Monitor Agreement by and among Quantic Regulatory Services, LLC and Hospira, Inc. dated January 3, 2007, pursuant to Paragraph III of the Order to Maintain Assets and, when made final, Paragraph III of the Decision and Order, issued in the above-referenced matter.

In according its approval, the Commission has relied upon the information submitted and representations made by Hospira and has assumed them to be accurate and complete.

By direction of the Commission.

Donald S. Clark
Secretary

cc: Owen Richards
President
Quantic Regulatory Services, LLC
5 N Regent Street, Suite 502
Livingston, NJ 07039
(973) 535-1734 (fax)